Becton Dickinson Price to Free Cash Flow Ratio 2012-2026 | BDX
Historical price to free cash flow ratio values for Becton Dickinson (BDX) since 2012.
| Becton Dickinson Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-06-12 | 146.24 | 20.23 | |
| 2025-12-31 | 150.54 | $7.23 | 20.82 |
| 2025-09-30 | 144.40 | $9.25 | 15.60 |
| 2025-06-30 | 132.17 | $8.82 | 14.99 |
| 2025-03-31 | 174.71 | $9.03 | 19.35 |
| 2024-12-31 | 172.26 | $10.21 | 16.88 |
| 2024-09-30 | 182.20 | $10.72 | 17.00 |
| 2024-06-30 | 175.89 | $11.28 | 15.60 |
| 2024-03-31 | 185.50 | $10.51 | 17.65 |
| 2023-12-31 | 182.05 | $9.20 | 19.78 |
| 2023-09-30 | 192.24 | $7.34 | 26.20 |
| 2023-06-30 | 195.64 | $6.06 | 32.30 |
| 2023-03-31 | 182.77 | $4.45 | 41.06 |
| 2022-12-31 | 187.04 | $4.67 | 40.03 |
| 2022-09-30 | 163.29 | $5.21 | 31.32 |
| 2022-06-30 | 180.05 | $4.25 | 42.37 |
| 2022-03-31 | 188.89 | $3.91 | 48.27 |
| 2021-12-31 | 177.99 | $6.86 | 25.96 |
| 2021-09-30 | 173.37 | $10.04 | 17.27 |
| 2021-06-30 | 170.97 | $11.27 | 15.18 |
| 2021-03-31 | 170.35 | $12.33 | 13.81 |
| 2020-12-31 | 174.71 | $10.10 | 17.29 |
| 2020-09-30 | 161.90 | $7.68 | 21.09 |
| 2020-06-30 | 165.92 | $8.80 | 18.85 |
| 2020-03-31 | 158.82 | $9.08 | 17.48 |
| 2019-12-31 | 187.36 | $10.32 | 18.16 |
| 2019-09-30 | 173.74 | $8.64 | 20.12 |
| 2019-06-30 | 172.57 | $8.86 | 19.48 |
| 2019-03-31 | 170.46 | $7.57 | 22.53 |
| 2018-12-31 | 153.32 | $7.11 | 21.56 |
| 2018-09-30 | 177.03 | $7.44 | 23.78 |
| 2018-06-30 | 162.02 | $7.36 | 22.00 |
| 2018-03-31 | 146.08 | $6.97 | 20.96 |
| 2017-12-31 | 143.81 | $7.84 | 18.35 |
| 2017-09-30 | 131.19 | $8.15 | 16.09 |
| 2017-06-30 | 130.15 | $6.25 | 20.84 |
| 2017-03-31 | 121.90 | $8.58 | 14.20 |
| 2016-12-31 | 109.57 | $7.99 | 13.72 |
| 2016-09-30 | 118.43 | $8.58 | 13.81 |
| 2016-06-30 | 111.34 | $9.16 | 12.16 |
| 2016-03-31 | 99.28 | $7.76 | 12.80 |
| 2015-12-31 | 100.32 | $6.11 | 16.41 |
| 2015-09-30 | 86.00 | $5.46 | 15.74 |
| 2015-06-30 | 91.42 | $4.30 | 21.24 |
| 2015-03-31 | 92.28 | $4.11 | 22.48 |
| 2014-12-31 | 89.07 | $5.21 | 17.11 |
| 2014-09-30 | 72.53 | $5.53 | 13.12 |
| 2014-06-30 | 75.04 | $6.84 | 10.97 |
| 2014-03-31 | 73.93 | $6.73 | 10.98 |
| 2013-12-31 | 69.44 | $6.21 | 11.19 |
| 2013-09-30 | 62.54 | $5.67 | 11.03 |
| 2013-06-30 | 61.48 | $4.72 | 13.03 |
| 2013-03-31 | 59.18 | $5.45 | 10.87 |
| 2012-12-31 | 48.13 | $5.27 | 9.14 |
| 2012-09-30 | 48.05 | $5.45 | 8.82 |
| 2012-06-30 | 45.45 | $5.03 | 9.04 |
| 2012-03-31 | 46.92 | $4.05 | 11.58 |
| 2011-12-31 | 44.88 | $3.83 | 11.71 |
| 2011-09-30 | 43.77 | $4.59 | 9.53 |
| 2011-06-30 | 51.18 | $4.35 | 11.78 |
| 2011-03-31 | 47.06 | $4.59 | 10.24 |
| 2010-12-31 | 49.70 | $4.63 | 10.73 |
| 2010-09-30 | 43.35 | $4.00 | 10.84 |
| 2010-06-30 | 39.35 | $4.39 | 8.97 |
| 2010-03-31 | 45.57 | $4.43 | 10.29 |
| 2009-12-31 | 45.43 | $4.29 | 10.60 |
| 2009-09-30 | 39.99 | $3.90 | 10.24 |
| 2009-06-30 | 40.69 | $3.34 | 12.19 |
| 2009-03-31 | 38.18 | $3.29 | 11.61 |
| 2008-12-31 | 38.63 | $3.06 | 12.63 |
| 2008-09-30 | 45.10 | $3.85 | 11.72 |
| 2008-06-30 | 45.53 | $3.62 | 12.57 |
| 2008-03-31 | 47.92 | $3.08 | 15.55 |
| 2007-12-31 | 46.50 | $3.30 | 14.08 |
| 2007-09-30 | 45.49 | $2.56 | 17.80 |
| 2007-06-30 | 41.18 | $2.78 | 14.83 |
| 2007-03-31 | 42.36 | $2.61 | 16.22 |
| 2006-12-31 | 38.52 | $3.06 | 12.58 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $43.913B | $21.840B |
| Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| West Pharmaceutical Services (WST) | United States | $18.493B | 35.19 |
| Straumann Holding AG (SAUHY) | Switzerland | $16.902B | 0.00 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| Merit Medical Systems (MMSI) | United States | $4.072B | 19.84 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| STAAR Surgical (STAA) | United States | $1.309B | 0.00 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |